LUCENTIS JPC

— Novartis —

Ophthalmology

Brief

LUCENTIS® (ranibizumab injection) is a prescription medicine for the treatment of patients with wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), and diabetic macular edema (DME). Novartis launched the pre-filled syringe: lesser manipulation, more accurate dosage, cleaner… and clinicians to be convinced. The campaign included a set of scientific materials, audiovisual materials and e-detailing.

We motivated the sales force with an extraordinary event which won Gold for Best Internal Marketing in the ASPIDs award 2015.